With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...
Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...
Abbott Laboratories narrowed its full-year profit outlook, raising the midpoint slightly, as strong demand for its diabetes ...
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
Trinity Biotech’s Chief Technology Officer, Dr Gary Keating, added, “Our next phase of refinements, guided by this study’s positive results, will be tested in a second European pre-pivotal trial, ...
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by ...
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the ...